Júlia Tavares de Castro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Júlia Tavares de Castro has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Paulo Lee Ho
Centro Bioindustrial, Instituto Butantan, São Paulo 05503-900, SP, Brazil
2 shared publications - Alessandra Soares-Schanoski
Bacteriology Laboratory, Butantan Institute, Sao Paulo, Brazil
1 shared publication - Anne-Sophie Debrie
INSERM U629, Lille, France
1 shared publication - Camille Locht
Institut Pasteur de Lille, Inserm U1019, CNRS UMR9017, Centre for Infection and Immunity of Lille, CHU Lille, Inserm, University of Lille, Lille, France
1 shared publication Carolina Yumi Takano
Núcleo de Produção de Vacinas Bacterianas, Centro BioIndustrial, Instituto Butantan
1 shared publication- Eliane Namie Miyaji
Bacteriology Laboratory Instituto Butantan São Paulo Brazil
1 shared publication
Latest Publications
- Open Access
- 19 October 2021
- Published by Elsevier in EBioMedicine
- Vol. 73, 103642
Off balance: Interferons in COVID-19 lung infections
- 19 October 2021
- Published by Elsevier in EBioMedicine
- Vol. 73, 103642
Open AccessOff balance: Interferons in COVID-19 lung infections
- Open Access
- 16 January 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (1) , e0228055
Evaluation of inactivated Bordetella pertussis as a delivery system for the immunization of mice with Pneumococcal Surface Antigen A
Pneumococcal Surface Protein A (PspA) has been successfully tested as vaccine candidate against Streptococcus pneumoniae infections. Vaccines able to induce PspA-specific antibodies and Th1 cytokines usually provide protection in mice. We have shown that the whole cell pertussis vaccine (wP) or components from acellular pertussis vaccines, such as Pertussis Toxin or Filamentous Hemagglutinin (FHA), are good adjuvants to PspA, suggesting that combined pertussis-PspA vaccines would be interesting strategies against the two infections. Here, we evaluated the potential of wP as a delivery vector to PspA. Bordetella pertussis strains producing a PspA from clade 4 (PspA4Pro) fused to the N-terminal region of FHA (Fha44) were constructed and inactivated with formaldehyde for the production of wPPspA4Pro. Subcutaneous immunization of mice with wPPspA4Pro induced low levels of anti-PspA4 IgG, even after 3 doses, and did not protect against a lethal pneumococcal challenge. Prime-boost strategies using wPPspA4Pro and PspA4Pro showed that there was no advantage in using the wPPspA4Pro vaccine. Immunization of mice with purified PspA4Pro induced higher levels of antibodies and protection against pneumococcal infection than the prime-boost strategies. Finally, purified Fha44:PspA4Pro induced high levels of anti-PspA4Pro IgG, but no protection, suggesting that the antibodies induced by the fusion protein were not directed to protective epitopes.
- 16 January 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (1) , e0228055
Open AccessEvaluation of inactivated Bordetella pertussis as a delivery system for the immunization of mice with Pneumococcal Surface Antigen A
Pneumococcal Surface Protein A (PspA) has been successfully tested as vaccine candidate against Streptococcus pneumoniae infections. Vaccines able to induce PspA-specific antibodies and Th1 cytokines usually provide protection in mice. We have shown that the whole cell pertussis vaccine (wP) or components from acellular pertussis vaccines, such as Pertussis Toxin or Filamentous Hemagglutinin (FHA), are good adjuvants to PspA, suggesting that combined pertussis-PspA vaccines would be interesting strategies against the two infections. Here, we evaluated the potential of wP as a delivery vector to PspA. Bordetella pertussis strains producing a PspA from clade 4 (PspA4Pro) fused to the N-terminal region of FHA (Fha44) were constructed and inactivated with formaldehyde for the production of wPPspA4Pro. Subcutaneous immunization of mice with wPPspA4Pro induced low levels of anti-PspA4 IgG, even after 3 doses, and did not protect against a lethal pneumococcal challenge. Prime-boost strategies using wPPspA4Pro and PspA4Pro showed that there was no advantage in using the wPPspA4Pro vaccine. Immunization of mice with purified PspA4Pro induced higher levels of antibodies and protection against pneumococcal infection than the prime-boost strategies. Finally, purified Fha44:PspA4Pro induced high levels of anti-PspA4Pro IgG, but no protection, suggesting that the antibodies induced by the fusion protein were not directed to protective epitopes.